drugset / Trial / NCT00004831
Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria
Completed
20 enrolled
FDA Office of Orphan Products Development
St. Luke's-Roosevelt Hospital Center · collab
RandomizedCrossoverDouble-blindTreatment
Summary
OBJECTIVES: I. Determine the efficacy of cysteine hydrochloride in preventing or decreasing photosensitivity in patients with erythropoietic protoporphyria.
Timeline
- Start
- 1996-10
- Primary completion
- —
- Completion
- 1998-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cysteine | Other / unclassified | — | Oral |